Evaluation of treatment-associated eye toxicity after irradiation in childhood and adolescence—results from the Registry of the Evaluation of Side Effects after Radiotherapy in Childhood and Adolescence (RiSK)

Fenja Albrecht · Heidi Wolters · Yvonne Ziert · Beate Timmermann · Rolf-Dieter Kortmann · Christiane Matuschek · Christian Rübe · Carmen Martini · Hans Christiansen · Hans Theodor Eich · Normann Willich · Diana Steinmann

Received: 26 January 2021 / Accepted: 23 April 2021 / Published online: 7 June 2021
© The Author(s) 2021

Abstract

Purpose The aim of the study is to evaluate treatment-related acute and late eye toxicity associated with radiation therapy in childhood and adolescence as correlated with RT (radiotherapy) doses.

Methods From 2001 to 2016, a total of 1725 children and adolescents undergoing radiation therapy were prospectively documented in the Registry of the Evaluation of Side Effects after Radiotherapy in Childhood and Adolescence (RiSK). The RTOG/EORTC criteria were used to classify ocular acute and late effects. Uni- and multivariate analyses were carried out to evaluate the impact of patient age, pre-existing impairments, and radiation dose on ocular toxicity.

Results Of all documented patients, 593 received dose to the eye and formed the basis of this analysis. In 435 patients, information on acute reaction was available and graded 1, 2, 3, and 4 in 49, 17, 0, and 2 patients, respectively. Information on late toxicity was available in 268 patients and graded 1, 2, 3, and 4 in 15, 11, 11, and 5 patients, respectively. The acute toxicity rate was significantly higher in children who received a maximum dose > 50 Gy to the eye (\( p < 0.001 \)) and who had a pre-existing eye impairment (\( p < 0.001 \) in multivariate analysis). The development of late toxicity was significantly higher for patients experiencing acute toxicity and having received a radiation dose > 50 Gy.

Conclusion Acute and late toxicity both correlate with high radiation dose to the eye (>50 Gy) and acute toxicity additionally with pre-existing eye impairments.

Keywords Radiation · Eye · Late toxicity · Side effects · Childhood
Introduction

Approximately one third of pediatric oncology patients need radiation therapy during the treatment of their malignant disease [1, 2]. The survival rates have significantly improved during the past years, with the 5-year-survival rate nowadays being over 80% [3]. Therefore, evaluation of treatment-related acute or late adverse effects is of major importance [4]. The acute (defined from start until 90 days after radiation therapy) and late (occurring after more than 90 days after radiation therapy) effects can be documented organ specifically by the RTOG/EORTC criteria [5, 6].

The eye, specifically the lens, is a sensitive structure and may develop relevant acute and late disorders, including cataract and retinopathy, after radiation therapy in children and adolescents [7–10].

To standardize the documentation of acute and late effects after radiation therapy in pediatric patients the Registry of the Evaluation of Side Effects after Radiotherapy in Childhood and Adolescence (RiSK) was founded in 2001 by the German Working Group of Paediatric Radio-Oncology (APRO) chaired by N. Willich, Münster. Financial support was provided by the Deutsche Kinderkrebsstiftung. In addition to the basic data of the radiation therapy, the acute and late effects to relevant organs at risk were documented according EORTC/RTOG [6] for each patient. Evidence of a correlation between radiation dose, radiation volume, and occurrence of acute and late effects in several organs, such as liver, lung, and thyroid gland has already been published using the RiSK database [11–13].

The aim of this study was to evaluate treatment-associated acute and late effects in the eye after radiation therapy in childhood and adolescence under consideration of the radiation dose–response relationship and further influencing factors.

### Materials and methods

The Registry of the Evaluation of Side Effects after Radiotherapy in Childhood and Adolescence includes altogether 1725 children and adolescents in 62 German centers, who underwent radiation therapy between 2001 and 2016. A standardized documentation of the applied radiotherapy including doses to organs at risk and adverse events based on RTOG/EORTC criteria of the patients was carried out and recorded in the database [1, 2, 6]. The classification of acute and late effects of the eye is displayed in Table 1. The Ethics Committee of the University Hospital Münster approved this project before starting documentation.

Of the 1725 registered children and adolescents, all patients having received any dose to the eye were included in this evaluation (n = 593). Also patients with total body irradiation (TBI) were included, as well as patients with an eye disorder already existing before radiation therapy. Patients with re-irradiation close to the eye and those with missing data were excluded.

In the registry, the radiation doses to the right eye and left eye were documented separately. For evaluation, we used the maximum dose (right or left eye), determined as Dmax, for the further statistical analysis (Table 2). To better analyze the influence of the irradiation dose on ocular toxicity, a classification based on the Dmax value was performed (referring to Whelan et al.), as listed in Table 2; [7]. Late toxicity had been documented in most patients at each follow-up (median 2.5 follow-ups [range 1–11]) and the maximum level of late toxicity reported was used for the analysis. Also included in the analysis were the three most common diagnoses ALL, medulloblastoma, and rhabdomyosarcoma (Table 2).

### Statistical analysis

Statistical analyses were performed using the statistics program SPSS (IBM, Armonk, NY, USA) for Windows (Microsoft, Redmond, WA, USA). Inferential statistics are used in an exploratory manner for generating new hypotheses.

| Table 1 Maximum acute/late eye toxicity i(RTOG/EORTG criteria) [6] | Late toxicity on the eyes |
| --- | --- |
| **Maximum acute eye toxicity** | **Late toxicity on the eyes** |
| Grade 0 | No change | None |
| Grade 1 | Mild conjunctivitis with or without scleral injection/increased tearing | Asymptomatic cataract |
| Grade 2 | Moderate conjunctivitis with or without keratitis requiring steroids and/or antibiotics/dry eye requiring artificial tears/iritis with photophobia | Minor corneal ulceration or keratitis |
| Grade 3 | Severe keratitis with corneal ulceration/objective decrease in visual acuity or in visual fields/acute glaucoma/panophthalmitis | Symptomatic cataract |
| Grade 4 | Loss of vision (unilateral or bilateral) | Moderate corneal ulceration; minor retinopathy or glaucoma |
| | | Severe keratitis; severe retinopathy or detachment |
| | | Severe glaucoma |
| | | Panophthalmitis/Blindness |
### Table 2  Baseline patient characteristics

|                          | All patients (%) | Patients with documented acute toxicity (%) | Patients with documented late toxicity (%) |
|--------------------------|------------------|---------------------------------------------|-------------------------------------------|
| **Total**                | 593              | 435 (73.4)                                  | 268 (45.2)                                |
| **Sex**                  |                  |                                             |                                           |
| Male                     | 338 (57.0)       | 244 (56.1)                                  | 151 (56.3)                                |
| Female                   | 255 (43.0)       | 191 (43.9)                                  | 117 (43.7)                                |
| **Age in years (median)**| 8.48 years       | 8.68 years                                  | 8.62 years                                |
| (range 0.77–20.1 years)  |                 | (range 0.77–20.1 years)                     | (range 0.86–20.1 years)                   |
| **Age**                  |                  |                                             |                                           |
| 0–4 years                | 149 (25.1)       | 112 (25.7)                                  | 65 (24.3)                                 |
| 5–9 years                | 185 (31.2)       | 135 (31.0)                                  | 84 (31.3)                                 |
| 10–14 years              | 155 (26.1)       | 119 (27.4)                                  | 70 (26.1)                                 |
| 15–20 years              | 89 (15.0)        | 64 (14.7)                                   | 43 (16.0)                                 |
| **Most frequent diagnosis** |                |                                             |                                           |
| ALL                      | 114 (19.2)       | 58 (13.3)                                   | 45 (16.8)                                 |
| Rhabdomyosarcoma         | 86 (14.5)        | 84 (19.3)                                   | 58 (21.6)                                 |
| Medulloblastoma          | 63 (10.6)        | 47 (10.8)                                   | 28 (10.4)                                 |
| Astrocytic tumor (WHO grade I–IV) | 60 (10.1)   | 47 (10.8)                                   | 19 (7.1)                                  |
| Sarcoma                  | 27 (4.6)         | 23 (5.3)                                    | 14 (5.2)                                  |
| Lymphoma                 | 13 (2.2)         | 10 (2.3)                                    | 4 (1.5)                                   |
| AML                      | 27 (4.6)         | 10 (2.3)                                    | 13 (4.9)                                  |
| Ependymoma               | 29 (4.9)         | 25 (5.7)                                    | 12 (4.5)                                  |
| Craniopharyngioma        | 23 (3.9)         | 19 (4.4)                                    | 11 (4.1)                                  |
| Other                    | 151 (25.5)       | 112 (25.7)                                  | 64 (23.9)                                 |
| **Preexisting eye impairment** | 145 (24.5)   | 121 (27.8)                                  | 73 (27.2)                                 |
| **Median eye dose in Gy**| 46.20 Gy (range 0.0–69.0 Gy) | 51.10 Gy (range 0.0–69.0 Gy) | 48.05 Gy (range 0.0–68.4 Gy) |
| **Classification Dmax**  |                  |                                             |                                           |
| Group 1 (0–2.0 Gy)       | 21 (3.5)         | 12 (2.8)                                    | 7 (2.6)                                   |
| Group 2 (>2.0–5.0 Gy)    | 8 (1.3)          | 4 (0.9)                                     | 4 (1.5)                                   |
| Group 3 (>5.0–12.0 Gy)   | 124 (20.9)       | 55 (12.6)                                   | 52 (19.4)                                 |
| Group 4 (>12.0–20.0 Gy)  | 38 (6.4)         | 26 (6.0)                                    | 12 (4.5)                                  |
| Group 5 (>20.0–40.0 Gy)  | 68 (11.5)        | 54 (12.4)                                   | 32 (11.9)                                 |
| Group 6 (>40.0–50.0 Gy)  | 64 (10.8)        | 53 (12.2)                                   | 27 (10.1)                                 |
| Group 7 (>50.0 Gy)       | 270 (45.5)       | 228 (52.4)                                  | 131 (48.9)                                |
| **Total body irradiation** | 95 (16.0)     | 34 (7.8)                                    | 31 (11.6)                                 |
| **Chemotherapy**         |                  |                                             |                                           |
| Any CTx                  | 495 (83.5)       | 359 (82.5)                                  | 208 (77.6)                                |
| Before                   | 435 (87.9)       | 309 (71.0)                                  | 191 (71.3)                                |
| Simultaneous             | 260 (52.5)       | 196 (45.1)                                  | 106 (39.6)                                |
| After                    | 249 (50.3)       | 186 (42.8)                                  | 106 (39.6)                                |
| **Median time for last follow up (months)** | 25.27 months | 24.38 months | 27.04 months |

Continuous variables are reported as median (min–max), categorical variables are reported as absolute frequencies and relative frequencies (%)

**ALL** acute lymphatic leukemia, **AML** acute myelogenous leukemia, **CTx** chemotherapy
According to Fisher’s approach, p-values are interpreted as a metric measure of evidence against the respective null hypothesis. Thus, neither global nor local significance levels were determined, and no adjustment for multiplicity was applied. However, p-values < 0.05 were considered statistically significant. In addition to p-values, risk estimators (odds ratios [OR] or hazard ratios [HR]) and corresponding 95% confidence intervals (95% CI) were calculated, providing additional descriptive information on the probabilities of an event under certain exposures.

For describing the data, standard univariate statistical analyses were applied. Categorical variables are shown as absolute and relative frequencies. Continuous variables are shown as median [range: minimum–maximum]. Acute toxicity was analyzed as a binary variable (grade 1–4/grade 0). Fisher’s exact test was used to quantify the association between acute toxicity and binary categorical variables (sex, TBI, any chemotherapy, CTX before RT, CTX simultaneously with RT, CTX after RT, pre-existing eye impairment, protons). The nonparametric Mann–Whitney test was used to evaluate the influence of continuous variables, such as age and Dmax irradiation dose to the eye.

Since for the observation of late toxicity no fixed time interval was defined, the time until late toxicity (grade 1–4) was analyzed using time-to-event methods, such as Kaplan–Meier estimates, log-rank tests, and univariate Cox regressions.

Finally, variables with statistically significant influence in univariate analysis (+chemotherapy pre/simultaneous/post) were investigated in a multivariate statistical analysis, enabling the evaluation of a connection and dependencies between various variables. For the analysis of acute toxicity, multivariate logistic regression was performed and a Cox regression for late toxicity.

**Results**

From 2001 to 2016, 593 patients were included in this study who received a radiation dose to the eye (34.4%) and who were documented within the RiSK database. The basic characteristics of the patients, diagnosis, and treatment are shown in Table 2. 145 forms regarding pre-existing eye impairment were available. These include, for example, loss of vision, ptosis, eye muscle paresis, and strabismus. The median age of the patients was 8.48 years and the majority of patients received a radiation dose of more than 50 Gy to the eye (n = 270).

**Acute eye toxicity**

Acute toxicity regarding the eye was documented in 435 patients (73.4%, Table 2), whereof n = 367 had no (grade 0) reaction or grade 1, 2, or 4 in 49, 17, and 2 patients, respectively. The majority of patients received more than 50 Gy maximum dose to the eyes (52.4%). The basic data of the patients are shown in Table 2.

Univariate analysis revealed a statistically significant association between the radiation dose > 50 Gy to the eyes and acute toxicities, with an odds ratio of 1.97 (95% CI 1.14–3.38; p-value 0.017). The patients who developed acute toxicities were also statistically significantly more likely to have had a pre-existing eye impairment (for example, double vision, decreased vision, ptosis, nystagmus), chemotherapy before undergoing irradiation, or radiation with protons (Table 3). About one third of the patients with documented acute toxicity were irradiated with protons (33.8%). The median age of 6.5 years (range 0.77–18.4 years) of these patients is below the average age of all patients in the study. 77.6% of the proton irradiations were done with a maximum radiation dose to the eye (Dmax) > 50 Gy and the median Dmax was 54.50 Gy (compare median Dmax of 41.0 Gy in patients without proton irradiation). The diagnosis of rhabdomyosarcoma was statistically associated with acute toxicity in the analysis (p-value < 0.001, odds ratio 6.34 with 95% CI 3.62–11.11). The age group of 0–4 years had an increased risk of developing acute toxicity after irradiation. Other age groups (compare Table 2) show no statistically significant relationship.

Additional multivariate analysis was performed for acute toxicity considering the impact of several variables (listed in Table 5). The significant influence of a pre-existing eye impairment (OR 3.47 [95% CI 1.81–6.65], p-value < 0.001), the diagnosis rhabdomyosarcoma (OR 5.26 [95% CI 2.47–11.23], p-value < 0.001), and a tumor with direct influence on the vision or the eye due its localization (OR 3.77 [95% CI 1.92–7.40], p-value < 0.001), i.e., tumor location on the visual apparatus (directly on the eye, chiasma region, or posterior visual tract) and thus possible tumor-related toxicity to the eye, was also confirmed in the multivariate analysis. The class of Dmax irradiation dose to the eyes and age group were not included in the multivariate analysis due to univariate logistic regression not yielding a statistically usable result, the reason being an unequal distribution within the groups. In univariate analysis, Dmax > 50 Gy and > 40.0–50 Gy were considered as single categorial variables (see Table 3). Further results can be seen in Tables 3 and 5.

**Late eye toxicity**

In 268 patients (45.2%), late toxicity after radiotherapy regarding the eye was observed (Table 2). The median time to the last documented follow-up in registry was 27.04 months (range 2.2–194.0 months). A maximum late toxicity ≥ 0 oc-
### Table 3  Univariate influence on acute toxicity

| Variable                  | Toxicity grade 0 (%) | Toxicity grade 1–4 (%) | Odds ratio | 95% confidence limits | p-value |
|---------------------------|----------------------|------------------------|------------|-----------------------|---------|
| **Total**                 | 367 (84.4)           | 68 (15.6)              | –          | –                     | –       |
| **Pre-existing eye impairment** |                     |                        |            |                       |         |
| Yes                       | 84 (69.4)            | 37 (30.6)              | 4.02       | 2.35–6.87             | <0.001  |
| No                        | 283 (90.1)           | 31 (9.9)               | –          | –                     | –       |
| **Direct influence on vision due to tumor site** |                     |                        |            |                       |         |
| Yes                       | 149 (74.9)           | 50 (25.1)              | 4.06       | 2.28–7.24             | <0.001  |
| No                        | 218 (92.4)           | 18 (7.6)               | –          | –                     | –       |
| **Rhabdomyosarcoma**      |                      |                        |            |                       |         |
| Yes                       | 50 (59.5)            | 34 (40.5)              | 6.34       | 3.62–11.11            | <0.001  |
| No                        | 317 (90.3)           | 34 (9.7)               | –          | –                     | –       |
| **Protons**               |                      |                        |            |                       |         |
| Yes                       | 109 (74.2)           | 38 (25.9)              | 2.99       | 1.77–5.09             | <0.001  |
| No                        | 258 (89.6)           | 30 (10.4)              | –          | –                     | –       |
| **CTx pre**               |                      |                        |            |                       |         |
| Yes                       | 252 (81.6)           | 57 (18.5)              | 2.37       | 1.20–4.68             | 0.007   |
| No                        | 115 (91.3)           | 11 (8.7)               | –          | –                     | –       |
| **CTx simultaneous**      |                      |                        |            |                       |         |
| Yes                       | 159 (81.1)           | 37 (18.9)              | 1.56       | 0.928–2.626           | 0.060   |
| No                        | 208 (87.0)           | 31 (13.0)              | –          | –                     | –       |
| **CTx post**              |                      |                        |            |                       |         |
| Yes                       | 154 (82.8)           | 32 (17.2)              | 1.23       | 0.73–2.07             | 0.258   |
| No                        | 213 (85.5)           | 36 (14.5)              | –          | –                     | –       |
| **CTx all**               |                      |                        |            |                       |         |
| Yes                       | 301 (83.8)           | 58 (16.2)              | 1.27       | 0.62–2.62             | 0.323   |
| No                        | 66 (86.8)            | 10 (13.2)              | –          | –                     | –       |
| **Age 0–4 years**         |                      |                        |            |                       |         |
| Yes                       | 87 (77.7)            | 25 (22.3)              | 1.87       | 1.08–3.24             | 0.034   |
| No                        | 280 (86.7)           | 43 (13.3)              | –          | –                     | –       |
| **Dmax >40.0–50 Gy (group 6)** |                     |                        |            |                       |         |
| Yes                       | 40 (76.9)            | 12 (23.1)              | 1.75       | 0.87–3.54             | 0.151   |
| No                        | 327 (85.4)           | 56 (14.6)              | –          | –                     | –       |
| **Dmax >50 Gy (group 7)** |                      |                        |            |                       |         |
| Yes                       | 87 (77.7)            | 25 (22.3)              | 1.97       | 1.14–3.38             | 0.017   |
| No                        | 280 (86.7)           | 43 (13.3)              | –          | –                     | –       |

Categorial variables are reported as absolute and relative frequencies. Influence is reported as odds ratios and 95% confidence limits. P-values are from Fisher’s exact test.

CTx chemotherapy, Dmax maximum dose.

occurred in 268 patients, of whom n=226 showed grade 0 toxicity (grade 1 = 15, grade 2 = 11, grade 3 = 11). Five patients developed the highest degree of late toxicity (grade 4 = 5). Additional basic data of patients are shown in Table 2.

As described above, the influence of the different variables on development of late toxicity was determined by means of a survival analysis (Table 4). Within univariate analysis, a significant influence of previously occurring acute toxicity was identified (HR 7.53 [95% CI 4.01–14.15], p-value <0.001). Furthermore, simultaneous chemotherapy, a tumor with direct influence on the vision or the eye due to its localization, and proton irradiation were significantly correlated with the risk of late toxicity (Table 4). As in patients with acute toxicity, one third of the children (33.2%) with documented late toxicity were irradiated with protons. The median age of 6.8 years was also lower than the general study average. 85.4% of the children were irradiated with a radiation dose >50 Gy to the eye and the median Dmax was 55.4 Gy, which is clearly higher than in the children irradiated without protons (median Dmax 29.22 Gy). Children 0–4 years
Table 4  Univariate influence on late toxicity

|                                | Toxicity grade 0 (%) | Toxicity grade 1–4 (%) | Hazard ratios | 95% confidence limits | p-value |
|--------------------------------|----------------------|------------------------|---------------|-----------------------|---------|
| **Total**                      | 226                  | 42                     | –             | –                     | –       |
| **Pre-existing eye impairment**|                      |                        |               |                       |         |
| Yes                            | 60 (82.2)            | 13 (17.8)              | 1.66          | 0.85–3.23             | 0.132   |
| No                             | 167 (85.6)           | 28 (14.4)              |               |                       |         |
| **Direct influence on vision due to tumor seat** |                      |                        |               |                       |         |
| Yes                            | 90 (75.6)            | 29 (24.4)              | 3.11          | 1.58–6.13             | <0.001  |
| No                             | 2 (100)              | 0 (0)                  |               |                       |         |
| **Rhabdomyosarcoma**           |                      |                        |               |                       |         |
| Yes                            | 37 (63.8)            | 21 (36.2)              | 3.21          | 1.73–5.97             | <0.001  |
| No                             | 190 (90.5)           | 20 (9.5)               |               |                       |         |
| **Protons**                    |                      |                        |               |                       |         |
| Yes                            | 69 (77.5)            | 20 (22.5)              | 4.45          | 2.30–8.63             | <0.001  |
| No                             | 158 (88.3)           | 21 (11.7)              |               |                       |         |
| **TBI**                        |                      |                        |               |                       |         |
| Yes                            | 26 (83.9)            | 5 (16.1)               | 1.18          | 0.46–3.03             | 0.727   |
| No                             | 201 (84.8)           | 36 (15.2)              |               |                       |         |
| **Acute toxicity**             |                      |                        |               |                       |         |
| Yes                            | 22 (51.2)            | 21 (48.8)              | 7.53          | 4.01–14.15            | <0.001  |
| No                             | 205 (91.1)           | 20 (8.9)               |               |                       |         |
| **CTx pre**                    |                      |                        |               |                       |         |
| Yes                            | 157 (82.2)           | 34 (17.8)              | 1.84          | 0.81–4.19             | 0.139   |
| No                             | 70 (90.9)            | 7 (9.1)                |               |                       |         |
| **CTx simultaneous**           |                      |                        |               |                       |         |
| Yes                            | 85 (80.2)            | 21 (19.8)              | 1.99          | 1.06–3.76             | 0.029   |
| No                             | 142 (87.7)           | 20 (12.3)              |               |                       |         |
| **CTx post**                   |                      |                        |               |                       |         |
| Yes                            | 88 (79.5)            | 18 (20.5)              | 1.14          | 0.61–2.13             | 0.690   |
| No                             | 139 (85.8)           | 23 (22.5)              |               |                       |         |
| **CTx all**                    |                      |                        |               |                       |         |
| Yes                            | 172 (82.7)           | 36 (17.3)              | 2.05          | 0.79–5.30             | 0.129   |
| No                             | 55 (91.7)            | 5 (9.3)                |               |                       |         |
| **Age 0–4 years**              |                      |                        |               |                       |         |
| Yes                            | 50 (76.9)            | 15 (25)                | 5.04          | 1.15–22.07            | 0.032   |
| No                             | 177 (87.2)           | 26 (12.8)              |               |                       |         |
| **Dmax 0.0–2.0 Gy (group 1)**  |                      |                        |               |                       |         |
| Yes                            | 7 (3.1)              | 0 (0.0)                | n.s.r.        | n.s.r.                | n.s.r.  |
| No                             | 219 (96.9)           | 42 (100.0)             |               |                       |         |
| **Dmax > 2.0–5.0 Gy (group 2)**|                      |                        |               |                       |         |
| Yes                            | 4 (1.8)              | 0 (0.0)                | n.s.r.        | n.s.r.                | n.s.r.  |
| No                             | 222 (98.2)           | 42 (100.0)             |               |                       |         |
| **Dmax > 5.0–12.0 Gy (group 3)**|                      |                        |               |                       |         |
| Yes                            | 46 (20.4)            | 6 (14.3)               | n.s.r.        | n.s.r.                | n.s.r.  |
| No                             | 180 (79.6)           | 36 (85.7)              |               |                       |         |
| **Dmax > 12.0–20.0 Gy (group 4)**|                      |                        |               |                       |         |
| Yes                            | 10 (4.4)             | 2 (4.8)                | n.s.r.        | n.s.r.                | n.s.r.  |
| No                             | 216 (95.6)           | 40 (95.2)              |               |                       |         |
| **Dmax > 20.0–40.0 Gy (group 5)**|                      |                        |               |                       |         |
| Yes                            | 29 (12.8)            | 3 (7.1)                | n.s.r.        | n.s.r.                | n.s.r.  |
| No                             | 197 (87.2)           | 39 (92.9)              |               |                       |         |
### Table 4 (Continued)

| Toxicity grade 0 (%) | Toxicity grade 1–4 (%) | Hazard ratios | 95% confidence limits | p-value |
|----------------------|------------------------|---------------|-----------------------|---------|
| **Dmax >40.0–50.0 Gy (group 6)** |                         |               |                       |         |
| Yes                  | 22 (9.7)               | 5 (11.9)      | n.s.r.                | n.s.r.  |
| No                   | 204 (90.3)             | 37 (88.1)     |                       |         |
| **Dmax > 50 Gy (group 7)** |                         |               |                       |         |
| Yes                  | 106 (81)               | 26 (61.9)     | 2.92                  | 1.51–5.65 | <0.001 |
| No                   | 121 (88.3)             | 16 (38.1)     |                       |         |

Categorical variables are reported as absolute and relative frequencies. Influence on late toxicity is reported as hazard ratios and 95% confidence limits (from Cox regression). P-values are from log-rank test.

CTx chemotherapy, TBI total body irradiation, n.s.r. no statistical result

### Table 5

Results of the multivariable analysis of acute and late toxicity

| Acute toxicity grade 1–4 | Odds ratio | 95% confidence interval | p-value | Late toxicity grade 1–4 | Hazard ratio | 95% confidence interval | p-value |
|--------------------------|------------|-------------------------|---------|--------------------------|--------------|-------------------------|---------|
| Pre-existing eye impair- | 3.47       | 1.81–6.65               | <0.001  | Pre-existing eye impair- | 0.73         | 0.35–1.54               | 0.404   |
| ment                     |            |                         |         | ment                     |              |                         |         |
| Direct influence on vision due to tumor seats | 3.77       | 1.92–7.40               | <0.001  | Direct influence on vision due to tumor seats | 2.01 | 0.90–4.46 | 0.087 |         |
| Rhabdomyosarcoma         | 5.26       | 2.47–11.23              | <0.001  | Rhabdomyosarcoma         | 1.48         | 0.62–3.53               | 0.375   |
| Protons                  | 1.01       | 0.51–2.02               | 0.975   | Protons                  | 1.11         | 0.44–2.82               | 0.822   |
| CTX pre                  | 6.99       | 0.85–57.57              | 0.071   | CTX sim                  | 0.98         | 0.44–2.18               | 0.958   |
| TBI                      | 1.47       | 0.28–7.57               | 0.071   | Dmax > 50 Gy             | 2.31         | 1.05–5.10               | 0.038   |
| Acute toxicity           |            |                         |         |                          | 4.29         | 1.91–9.62               | <0.001  |

Logistic regression was performed for the dependent binary variable acute toxicity (grade 1–4 vs. grade 0). Cox regression was performed for the time until the maximal late toxicity (grade 1–4).

CTx chemotherapy, TBI total body irradiation

of age were particularly at risk for late sequelae of the eye, confirming the survival analysis with the HR of 5.04 (95% CI 1.15–22.07) and p-value 0.032. An analysis of the maximum irradiation dose to the eye (Dmax) proved to be difficult due to the lack of documentation in some groups of children concerning late toxicities. But a consideration of group 7 (Dmax >50 Gy) as a single variable showed a significant influence in univariate analysis (HR 2.92 [95%-CI 1.51–5.65], p-value <0.001).

As described in the statistical methods section, multivariate analysis of the influencing factors was subsequently performed (Table 5). The association with acute toxicity was also confirmed in multivariate analysis (HR 4.29 [95% CI 1.91–9.62], p-value <0.001). The risk of developing late toxicity after irradiation with more than 50 Gy (compare Fig. 1) was significantly increased, as shown by the p-value 0.038 (HR 2.31 [95% CI 1.05–5.10]). Other variables, such as the diagnosis of rhabdomyosarcoma, proton therapy, or a pre-existing eye impairment, did not show any significant influence on the development of late toxicities affecting the eye within this multivariate analysis (compare Table 5).

The patient records of the five patients with grade 4 toxicity were casuistically reviewed to demonstrate more precise information on the individual high-grade sequelae of radiation exposure. One patient showed radiation-induced optic atrophy with visual deterioration 1 year after the end of irradiation. In another patient, optic atrophy worsened after irradiation, so that a deterioration of vision was also described. Another child developed a severe sicca syndrome as a result of radiation. More detailed information on the course of the disease and examination reports from ophthalmologists are only partially available to the registry in the respective patient files. However, it can be stated that all three patients were irradiated with a Dmax > 50 Gy in the eye. One patient also corresponds to the age group 0–4 years, which in univariate analysis shows an increased risk of developing late toxicity in the eye.

Regrettably, for the other two patients, we had inaccurate and contradictory data regarding the demarcation between pre-therapeutic visual impairment and treatment-associated damage, which makes further consideration impossible. The cases demonstrate the significant dose dependence of the development of late toxicities. In addition, they also show the diversity of causes of late toxicity in detail (optic atrophy, sicca syndrome etc.), which cannot be further analyzed from the statistics and classification alone.
Discussion

The eye, mainly the lens, is a particularly radiation-sensitive organ and even low doses of radiation increase the risk for subsequent ocular disorders [7, 9]. Especially the effect of radiation on the lens with regard to development of cataract has been investigated in numerous studies [7–9, 14–16]. Whelan et al. indicated in their large cohort study of the Childhood Cancer Survivor Study (CCSS) that survivors have a significantly higher risk for all ocular damages [7]. Acute toxicity reactions predominantly affect the ocular anterior segment and can cause reactions such as conjunctivitis, keratitis, or blepharitis [17]. Acute toxicities (≥grade 1) did occur in our study in 11.5% of the patients. When analyzing the irradiation dose, the univariate analysis shows that a maximum radiation dose >50 Gy significantly increased the risk of developing acute toxicity. In other studies the risk was already increased at appreciably lower irradiation doses. According to the ICRP (International Commission on Radiological Protection), ocular pathologies other than lens opacity after acute or fractional exposures already occurred at radiation doses of 5–20 Gy [15]. It can be assumed that the risk of an acute toxicity reaction is also increased by radiation doses lower than 50 Gy. Considering that in our case, only very few patients with documented toxicity were documented in Dmax >2.0 Gy, >5.0–12.0 Gy, >12.0–20.0 Gy, and >20.0–40.0 Gy, statistical evaluation is not feasible. Acute toxicity reactions are usually reversible. For example, Gordon et al. described the self-limitation of acute complications after irradiation with 2–2.5 Gy to about 37 Gy in the treatment of orbital or conjunctival lymphomas [14]. Despite the frequent regression of acute reactions, the occurrence of toxicities and particularly severe chronic toxicities should not be underestimated—as our study impressively shows. As already demonstrated in another RISK-based study, high-grade acute toxicities are a risk factor for developing chronic toxicity reactions [18]. In our study, the presence of acute toxicity was also significantly associated with late sequelae (p-value < 0.001). Thus, it is an important conclusion that an acute toxicity reaction should be avoided if possible, in order to consequently minimize the risk of severe late sequelae.

In our study, late toxicity (grade 1–4) was determined in 7.08% of patients, of whom five showed grade 4 toxicity according to the RTOG criteria (Table 1). According to Barabino et al., late reactions are mainly due to permanent vascular damage and the resulting ischemia of ocular structures, which can lead to retinopathies, cataracts, or neuropathies (these sequelae have also been observed in other studies [19]) [17]. In their study, they summarized the effects of radiation on the individual orbital structures based on other studies and evaluated them according to a radiation dose relationship. The pathophysiology of irradiation-induced cataracts is additionally based on DNA damage of lens epithelial cells and the development of posterior subcapsular opacification by migration of abnormal cells [8, 14]. The publication of Whelan et al. from the CCSS examined six different kinds of ocular sequelae originating from an irradiation dose relationship [7]. The development of dry eyes, double vision, legal blindness, cataract, retinal conditions, and glaucoma was evaluated. The occurrence of eye sequelae was compared between survivors and a sibling control group. Patients answered specific questions about the occurrence of the six diagnoses in a self-questionnaire, repeated at 5 and 10 years after diagnosis. The analysis revealed an increased risk for survivors of developing a cataract, glaucoma, legal blindness, double vi-
sion, and dry eyes compared to siblings. The relationship between the irradiation dose to the eye and the risk of late complications also showed a defined correlation: a dose of 2–5 Gy significantly increased the risk of double vision and cataract. With a radiation dose of 5–12 Gy, a significant influence on the development of dry eyes and blindness was found. Retinal conditions were more frequent at doses of 20–40 Gy or more. It should be noted that the risk of all diseases increased with higher radiation doses (also observed specifically for cataract in Tinkle et al. [16]). Unfortunately, an exact evaluation of the influence of the irradiation dose to the eye on development of late toxicity was not possible in our study, as the number of patients in the different dose groups was insufficient. However, in the multivariate analysis of the single variable Dmax > 50 Gy, the survival analysis showed significance with a p-value 0.038. Of the 42 patients with documented late toxicity ≥ grade 1, 25 received a radiation dose of > 50 Gy to the eye. We conclude that the risk of toxicity is lower for radiation doses below 50 Gy than above 50 Gy. An irradiation dose of 50 Gy to the eye can be observed as a critical threshold [17]. Although the context of the study by Jazmati et al. is different due to the palliative situation of the irradiated children, no late toxicities were documented in this study with a mean dose of 36 Gy [20]. Another limitation of our study when compared to other studies was the inability to examine the individual specific secondary disorder. The RiSK uses the graduation of consequential damage according to RTOG/EORTC; therefore, a differentiation of specific diseases is not available [6]. The same degree can be assigned by different ocular diseases and their severity (see Table 1). An advantage of this approach can be observed. Radiation-induced damage to one structure can additionally negatively affect other surrounding ocular structures [14]. The indicated degree of toxicity is able to offer an overall impression of the acute and late sequelae, in addition to an overall assessment of the eye and vision.

The influence of chemotherapy as a risk factor for toxicity after RT has been investigated in several studies [7, 9, 11–13]. Cytostatic drugs such as platinum, vinca alkaloids, taxane, methotrexate, or even 5-flourouracil can come with ocular toxic side effects [21, 22]. For example, vincristine, frequently used in chemotherapy of various malignant diseases, can cause diplopia, ptosis, optic atrophy, or transient cortical blindness [21, 22]. Our study also showed a significant relationship between chemotherapy and toxicities. In acute toxicity, chemotherapy prior to radiation showed notably significant effects, as did simultaneous chemotherapy for late secondary damage. The relationship between simultaneous chemotherapy and high-grade toxicities has already been suggested by Pixberg et al. [18].

Rhabdomyosarcoma was the most common diagnosis of the included patients in this study and represented a statistically significant risk factor for the development of acute (in uni- and multivariate analysis) and late toxicity (in univariate analysis). In the publication of Eade et al., rhabdomyosarcoma is mentioned as the most frequent primary tumor of the orbit in childhood [23]. Main late complications after treatment are cataract and keratopathy. Other studies also proved ocular late effects after rhabdomyosarcoma therapy in childhood and adolescence [23, 24]. The relevant pre-existing eye impairment also increased the risk for toxicity—in case of acute toxicity even significantly in uni- and multivariate analysis. It cannot be derived from the RiSK data whether previous damage to the eye was caused by the tumor, although it can be assumed. An ophthalmological examination ahead of commencing irradiation can indicate an existing damage, which can be prone to exacerbation [17]. This may help to predict or even prevent a possible risk of secondary late effects and aggravation of existing ocular restrictions.

Children aged 0–4 years had a significantly higher risk of developing acute or late toxicity in univariate analyses. Most ocular structures develop in early childhood [25]. For example, lens thickness decreases and the individual compartments change their depth and length. Due to this early childhood development, it can be assumed that irradiation at this age has an influence on development and the eye is particularly susceptible to secondary damage. The significance in our statistical evaluation can be attributed to this influence. The analysis of the influence of proton irradiation must be viewed critically with regard to any possible impact on toxicity. Even when the univariate analysis of acute toxicity and late toxicity suggests a significant influence, this finding could not be confirmed in multivariate analysis. Most probably, the observed effect was caused by a selection bias. With proton therapy, particularly very young patients diagnosed with rhabdomyosarcoma receiving relatively high radiation doses were treated. Accordingly, our descriptive evaluations show a significantly higher median irradiation dose to the eye with protons when compared to photons. A high median radiation dose for proton irradiation can also be observed in other studies such as Doyen et al. (median total prescribed dose 55.8 Gy) [26]. Therefore, the use of protons cannot be associated with any increased risk for toxicity within this study.

The patients with the highest degree of late eye toxicity were casuistically evaluated. But also the consequential damages, which were classified with grade 2 or 3, represent a major limitation in the quality of life of the affected patients. A descriptive evaluation of this collective (n=22) shows a median age of 4.5 years and an average Dmax of 50.5 Gy (13 of the 22 patients belong to Dmax group 7). Also interesting is the fact that 59.1% had already documented acute damage to the eye after irradiation.
In radiotherapy, the technical possibilities are constantly being developed with the aim of minimizing acute and late sequelae. Techniques such as IMRT or tomotherapy make it possible to irradiate pathological tissue in a more conformal manner while sparing healthy surrounding tissue [27, 28]. It is well known that in addition to the radiation dose used, the volume irradiated has a major impact on organs at risk (OARs) and this is minimized by new radiation methods [29]. Maximum doses are often determined for OARs to minimize sequelae (for example, <55 Gy at the base of the skull, optic chiasm, optic nerve) [26]. Nevertheless, studies show that late effects occur even with these techniques [28]. In 2020, Bishr et al. show that radiation therapy is used very commonly in pediatric cancer treatment—both curatively and palliatively [30]. Children with radiation-related late effects are forced to live with these effects for significantly more years, and this can have a significant impact on quality of life [28]. This is why, in our view, it is so important to minimize and ideally prevent radiation damage in childhood.

There are limitations of our study. Unfortunately, we did not have all information on late toxicity for our cohort and FU time was still limited. Moreover, information on specific ocular disorders following radiotherapy was not given. Finally, when considering all subgroups and techniques used, the number of patients was still restricted. Data were not analyzed in a matched-pair analysis. Furthermore, we did not investigate consecutive interventions or therapies for eye disorders, which would be of interest to understand the impact of any specific disorder and to better define the role of RT in the future. To conclude, an irradiation dose of >50 Gy to the eye represented a significantly increased risk for toxicity of the eye. However, young age and RMS diagnosis showed a significant influence as well. To our knowledge, RiSK was the only prospective registry for recording acute and late effects of radiotherapy in childhood and adolescence. The documentation was carried out by qualified radio-oncologists and based on standardized medical follow-up examinations, which is crucial for the aftercare of specific side effects [31]. Therefore, the data from the RiSK must be considered objective with regard to eye damage. Other studies dealing with the same problem are analyzed on the basis of information from patient self-interviews, which are subjective views of the patients [7, 9].

**Conclusion**

The eye is very sensitive to radiation and, especially in early childhood, any exposure to radiation can have an effect on the development of the eye and the occurrence of secondary damage. Our study indicates that different factors have an influence on the development of eye toxicity after irradiation. Acute and late toxicity seem to be correlated with a high radiation dose to the eye (>50 Gy). Also, patients having treatment for a rhabdomyosarcoma diagnosis seem to be particularly prone to developing eye disorders. However, even below a dose of 50 Gy there is a certain risk for severe acute and especially chronic toxicities. Therefore, radiation doses to the eye should generally be kept as low as possible to reduce the risk of toxicity. Any radiation therapy in a child and in the craniofacial area has to be carefully balanced against the risk for life-long sequelae.

**Funding** The RiSK register was financially supported by Deutsche Kinderkrebshilfe. No funding was received for conducting this study.

**Author Contribution** All authors have made a decisive contribution to the production of this manuscript. The analyses performed and the first draft of the manuscript were done by FA and DS. All authors commented on previous versions. The version submitted has been approved and supported by all the coauthors listed.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** F. Albrecht, H. Wolters, Y. Ziert, B. Timmermann, R.-D. Kortmann, C. Matuschek, C. Rübe, C. Martini, H. Christiansen, H.-T. Eich, N. Willich, and D. Steinmann declare that they have no competing interests.

**Ethical standards** Ethics approval: The Ethics Committee of the University Hospital Münster approved the register before starting documentation in 2001. Thus, this study does not require further approval by the ethics committee. Consent to participate: The included patients or their parents all gave their prior consent to the use of their data for medical research purposes. This was provided at the time of admission to RiSK. The declarations of consent are archived for each patient. Consent for publication: Participants consented to the processing and publication of the data, under the condition of anonymization, for medical research purposes by a signed informed consent form. Submission of the consent form: https://www.ukm.de/fileadmin/ukminternet/daten/kliniken/strahlentherapie/dokumente/RiSK/Einverstaendnisverjaehrung_RiSK_final_2012-08-03.pdf

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Willich N, Ernst I, Pape H et al (2009) Evaluation of side effects after radiotherapy in childhood and adolescence: from retrospec-
